Home
-
Blockbuster Contenders: The Class of 2026
What new products, recently or expected to launch in 2026, show blockbuster potential or will be transformative in key therapeutic areas? A look at the companies and products rising to the top of the class.
-
CDMOs Roll Out Expansions for Parenteral Drugs
The global injectables drugs market is projected for strong growth, driven by demand in biologics and specialty therapeutics. In response, CDMOs/CMOS are expanding production capacity. What are the latest expansions?
-
Big Pharma Outlook: CEOs Making the Moves
As the industry moves further into 2026, what are larger issues impacting industry and company performance? .A view from the C-suite.
DCAT MEMBER COMPANY COMMUNITY
-
New DCAT Member Company Alert
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view…
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance)news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement to share for…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
New Episode: Production to Prescription Podcast: 2025: The Bio/Pharma Industry’s Year in Review
Without question, evolving US tariff and trade policy was the story of the year in 2025, and how such policy will be implemented looms large. At the same time, the…
